SCHEMBL4903971

SCHEMBL4903971

CSc1nc(O)c(C#N)c(-c2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
DCUN1D1 Q96GG9 3/20 0.42
LMNA P02545 3/20 0.39
RXFP1 Q9HBX9 2/20 0.39
THRB P10828 2/20 0.39
ALDH1A1 P00352 1/20 0.38
MAPK14 Q16539 1/20 0.38
KMO O15229 2/20 0.38
KDM1A O60341 3/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 2/20 0.37
ALOX15 P16050 2/20 0.37
LDHA P00338 1/20 0.37
LDHB P07195 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4906040 0.86 CYP1A2 (0.71) KMT2ACYP1A2CYP2C9CYP2C19DCUN1D1
SCHEMBL4908047 0.82 KMO (0.42) KMT2ACYP1A2CYP2C9CYP2C19DCUN1D1
SCHEMBL4905668 0.79 KDM1A (0.44) KMT2ACYP1A2CYP2C9CYP2C19DCUN1D1
SCHEMBL4906965 0.79 CA12 (0.39) DCUN1D1MAPK14KMOKDM1ACA12
SCHEMBL4905895 0.77 ALDH1A1 (0.47) KMT2ACYP1A2CYP2C9CYP2C19DCUN1D1
SCHEMBL4421002 0.76 RXFP1 (0.61) KMT2ADCUN1D1LMNARXFP1KDM1A
SCHEMBL4909570 0.76 BRAF (0.39) DCUN1D1LMNAALDH1A1MAPK14KMO
SCHEMBL4904088 0.75 MAPK14 (0.38) DCUN1D1ALDH1A1MAPK14KMOCA12
SCHEMBL4909122 0.75 RXFP1 (0.43) KMT2ACYP1A2CYP2C9CYP2C19LMNA
SCHEMBL4898170 0.75 KMT2A (0.43) KMT2ACYP1A2CYP2C9CYP2C19RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF KMT2A 3422/4885CYP1A2 1768/4885CYP2C9 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.